Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Grifols introduces Niuliva to the market

Grifols introduces Niuliva to the market

4th September 2009

Grifols has announced that its human anti-hepatitis B immunoglobulin drug Niuliva has become available to several countries in the EU.

It has been approved for the treatment of hepatitis B virus reinfection after liver transplantation, as well as for hepatitis B-induced liver failure during the maintenance phase in non-replicator patients and is an intravenous drug.

Available in both pre-filled syringe or vial form as well as in an optimum pharmaceutical form, the drug is the first intravenous human anti-hepatitis B immunoglobulin to be registered in Spain.

The company expects that it will be approved for use in a wide number of other countries worldwide over the coming months.

Upon revealing the availability of the drug, Grifols highlights that around 350 million people are chronically infected worldwide by Hepatitis B and that the virus is the most frequent cause of chronic liver disease.

Earlier this year Grifols acquired a stake in Cardio3 BioSciences, which enabled it to further its research and development programme.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.